Please use this identifier to cite or link to this item:
|Title:||The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis||Authors:||Chiaravalloti, Nancy D.
Amato, Maria Pia
Moore, Nancy B.
Rocca, Maria Assunta
Sandroff, Brian M.
|Issue Date:||2020||Publisher:||SPRINGER HEIDELBERG||Source:||Journal of neurology (Print) = Zeitschrift fÃ¼r Neurologie (1974),||Status:||Early view||Abstract:||Objective Individuals with pre-existing chronic illness have shown increased anxiety and depression due to COVID-19. Here, we examine the impact of the COVID-19 pandemic on emotional symptomatology and quality of life in individuals with Progressive Multiple Sclerosis (PMS). Methods Data were obtained during a randomized clinical trial on rehabilitation taking place at 11 centers in North America and Europe. Participants included 131 individuals with PMS. Study procedures were interrupted in accordance with governmental restrictions as COVID-19 spread. During study closure, aCOVID Impact Surveywas administered via telephone or email to all participants, along with measures of depressive symptoms, anxiety symptoms, quality of life, and MS symptomatology that were previously administered pre-pandemic. Results 4% of respondents reported COVID-19 infection. No significant changes were noted in anxiety, quality of life, or the impact of MS symptomatology on daily life from baseline to lockdown. While total HADS-depression scores increased significantly at follow-up, this did not translate into more participants scoring above the HADS threshold for clinically significant depression. No significant relationships were noted between disease duration, processing speed ability or EDSS, and changes in symptoms of depression or anxiety. Most participants reported the impact of the virus on their psychological well-being, with a little impact on financial well-being. The perceived impact of the pandemic on physical and psychological well-being was correlated with the impact of MS symptomatology on daily life, as well as changes in depression. Conclusions Overall, little change was noted in symptoms of depression or anxiety or overall quality of life.||Notes:||Chiaravalloti, ND (corresponding author), Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA.; Chiaravalloti, ND (corresponding author), Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
|Other:||Chiaravalloti, ND (corresponding author), Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA ; Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. email@example.com||Keywords:||COVID-19;Depression;Anxiety;Progressive multiple sclerosis;Quality of life||Document URI:||http://hdl.handle.net/1942/32786||ISSN:||0340-5354||e-ISSN:||1432-1459||DOI:||10.1007/s00415-020-10160-7||ISI #:||WOS:000561058200003||Rights:||Springer-Verlag GmbH Germany, part of Springer Nature 2020||Category:||A1||Type:||Journal Contribution||Validations:||ecoom 2021|
|Appears in Collections:||Research publications|
Show full item record
Files in This Item:
|Published version||944.17 kB||Adobe PDF||View/Open Request a copy|
WEB OF SCIENCETM
checked on May 22, 2022
checked on May 25, 2022
checked on May 25, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.